Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.70 | N/A | -4.17% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.70 | N/A | -4.17% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed cautious optimism about future developments. They noted that while the EPS was below expectations, the company is focused on its long-term goals.
Management highlighted ongoing progress in clinical trials.
They emphasized commitment to advancing their pipeline despite current losses.
Protagonist Therapeutics reported a wider-than-expected loss per share, which may raise concerns among investors. However, the stock still reacted positively, gaining 2.11%, likely due to management's focus on clinical progress and long-term strategy. Investors may view this as a sign of resilience despite the earnings miss.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SIMON PPTY GROUP INC REIT
Nov 1, 2021